Stockreport

IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio IBRX has entered a new phase as a commercial-stage immunotherapy developer. The company's near-term trajectory is closely tied to a single asset, Anktiva, w [Read more]